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Abstract
Background: In experimental systems, interference with coagulation can affect tumor biology.
We suggested that abnormal coagulation could be a negative predictor for response to
immunotherapy and survival among patients with metastatic renal cell carcinoma (MRCC).
Methods: To address this issue, retrospective analysis of 289 previously untreated MRCC patients
entering on institutional review board-approved clinical trials was conducted between 2003 and
2006. In addition, two groups of MRCC patients with (n = 28) or without (n = 28)
hypercoagulability were compared in a case-control study. Baseline and treatment characteristics
were well balanced.
Results: Hypercoagulability was present at treatment start in 40% of patients. Median baseline
fibrinogen was 6.2 mg/dl. Serious disorders were found in 68% of patients. Abnormal coagulation
was strongly associated with a number of metastatic sites (2 and more metastatic sites vs. 0–1 (P
= .001). Patients with high extent of hypercoagulability had significantly higher number of metastatic
sites (P = .02). On univariate analysis, patients with hypercoagulability had significantly shorter
overall survival than patients with normal coagulation; median survivals of 8.9 and 16.3, respectively
(P = .001).
Short survival and low response rate also were significantly associated with hypercoagulability in a
case-control study. Median survival was 8.2 months and 14.6 months, respectively (P = .0011).
Disease control rate (overall response + stable disease) was significantly higher in patients with
normal coagulation: 71.4 versus 42.9% (P = .003).
Conclusion: Hypercoagulability disorders were found to be prognostic factor for response rate
to systemic therapy and survival in patients with MRCC.
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Background
Renal cell carcinoma (RCC) is the most common cancer
of the kidney [1]. An estimated 16,000 new cases of RCC
were diagnosed in Russian Federation in 2005. Up to 30%
of patients with RCC present with metastatic disease every
year, and recurrence develops in approximately 40% of
patients treated for localized tumor [2].
High-dose interleukin-2 therapy rarely induces a durable
complete response, and interferon alpha provides only a
modest survival advantage. Overall response rate with
these cytokines is low (5 to 20%) [3]. A growing under-
standing of the underlying biology of RCC has led to
development of vascular endothelial growth factor
(VEGF) inhibitors, such as sunitinib and sorafenib [4,5].
The promising data with VEGF inhibition in metastatic
RCC have established new opportunities for improving
outcomes in this historically resistant malignancy. Com-
bination of targeted therapy and biological agents has
promising results. However, several questions remain
unanswered concerning their optimal use.
Improved treatment strategies and/or better methods of
identifying those patients likely to benefit from medical
therapy are needed.
Considerable data is now available to help predicting the
outcome for patients with advanced renal cancer receiving
systemic therapy. Factors that have been variably associ-
ated with response and survival include Karnofsky per-
formance status < 80%, time from diagnosis to treatment
< 12 months, corrected serum calcium > 10 mg/dL,
Hemoglobin below the lower limit of normal, and LDH >
1.5 times the upper limit of normal. Patients considered
to have a favorable profile are those with no poor prog-
nostic factors present; intermediate group patients have
1–2 factors present; and patients with an unfavorable pro-
file have > 2 factors present. This is a Memorial Sloan Ket-
tering Cancer Center (MSKCC) model developed by
Motzer et al. [6,7].
Several poor prognostic factors have been identified in
ARCC trial (efficacy and safety of temsirolimus in previ-
ously untreated patients with metastatic RCC), such as
number of organs with metastases (2 and more) and inter-
val from original diagnosis to the start of systemic therapy
[8].
Moreover, disorders in hemostatic system such as hyper-
coagulability can impact on tumor growth.
We evaluated rate of abnormal coagulation in metastatic
RCC, correlation between levels of disorders, number of
metastatic sites; determine response rate, disease progres-
sion and survival in patients with or without abnormal
coagulation who had received immunotherapy.
Methods
Patients
The study population consisted of patients who had met-
astatic RCC with any type of histology. Patients who had
not received previous systemic therapies for metastatic
disease were included in the analysis. Other key eligibility
criteria for analysis included the presence of measurable
disease, adequate hepatic, renal, and cardiac function.
Patients were ineligible if they had brain metastases, life
expectancy of less than 4 month, thrombocytosis, indica-
tion for anticoagulant treatment (for example, mechanic
heart valves, inferior vena cava filter, previous venous
thromboembolism, or atrial fibrillation), medical contra-
ception.
Study design and methods of evaluation
Retrospective analysis of 289 patients entering on institu-
tional review board-approved clinical trials was con-
ducted between 2003 and 2006 at the N.N. Blokhin
Russian Cancer Research Center.
In addition, two groups of patients with (n = 28) or with-
out (n = 28) hypercoagulability were compared in a case-
control study. Baseline and treatment characteristics were
well balanced. All 56 patients previously received at least
2 cycles of low-dose immunotherapy (interleukin-2, 1
MU, i.v, 3 tiw and interferon alfa 2b, 5 MU, s.c, 3 tiw – 3
weeks on, 3 weeks off). Patients were compared by
MSKCC prognostic score. We measured the primary end-
point (differences in disease progression rate) from the
date of treatment start until the date of evaluation for
response rate after two treatment cycles, and the second-
ary end-point (median overall survival) from the date of
treatment start until the date of death. The progression of
disease was determined on the basis of findings of com-
puted tomography (CT) or magnetic resonance imaging
(MRI), clinical progression, or death, with the use of the
Response Evaluation Criteria in Solid Tumors (RECIST).
Factors evaluated in all patients were: age, gender, time
from diagnosis to on-study, number of metastatic sites,
MSKCC prognostic factors, fibrinogen, fibrin monomer,
and D-dimer. The coagulation profile was assessed before
the start of the treatment. Pretreatment level was used to
classify patients by the presence or absence of hypercoag-
ulability. Hypercoagulability was defined as elevation of
main coagulation factors (Table 1). Normal coagulogram
was defined as normal values of fibrinogen (≤ 4.0 mg/dl),
D-dimer (≤ 0.248 mg/ml) and negative fibrin monomer.
Patients who initially had normal levels of coagulation
factors and later developed hypercoagulability were cate-Journal of Experimental & Clinical Cancer Research 2009, 28:30 http://www.jeccr.com/content/28/1/30
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gorized as having normal coagulation and were included
in the analysis.
All coagulograms were performed on an automatic STA
COMPACT analyzing device.
Statistical analysis
The hypercoagulability was summarized using frequency
counts. Summary statistics (Mean, Median, and Propor-
tion) was used to describe patient baseline characteristics.
An estimate of the overall response rate/disease progres-
sion rate was made by taking number of patients with a
response/progression of disease (number of evaluable
patients). The secondary endpoint was a difference in
overall survival between patients treated with immuno-
therapy and hypercoagulability versus patients with nor-
mal coagulation was tested using a 2-sided Log-rank test
(α = 0.05). Patients alive at the end of follow-up were cen-
sored. The Kaplan-Meier method was used to estimate sur-
vival outcomes. Multiple factors were assessed using Cox
proportional hazards regression model. The chi-square
test and Fisher exact test were used to compare patient
groups.
Results
Demographics
Two hundred and eighty nine untreated patients were
enrolled on trials. Seventy-eight percent of patients were
males, and median age was 61.8 years. The demographics
are described in Table 2.
Of 289 patients whose medical charts were reviewed,
hypercoagulability was present at treatment entry in 40%
of patients. Median baseline fibrinogen was 6.2 mg/dl
(95% CI; 3.4–9). Thirteen (11%), 24 (21%), and 79
(68%) coagulation profiles were classified as low, inter-
mediate, or high grade hypercoagulability based on the
previously described model.
We analyzed association of hypercoagulability with
MSKCC prognostic factors as well as number of metastatic
sites. 46, 22 and 44% patients in groups of favorable,
intermediate and poor prognosis respectively had hyper-
coagulability. Abnormal coagulation was strongly associ-
ated with number of metastatic sites (2 and more
metastatic sites vs. 0–1 (P = .001). Patients with high
grade of hypercoagulability had significantly higher
number of metastatic sites (4 and more vs. 1–3; P = .02).
Association of hypercoagulability with disease-progression 
under immunotherapy. A case-control study
Two groups of patients were compared in a study. Baseline
characteristics were well balanced and these groups were
compared by modified MSKCC prognostic score includ-
ing predictors of short survival from ARCC trial (Table 3).
Sixteen patients of study group (57.1%) and eight patients
of control group (28.5%) had disease progression after 2
treatment cycles. Differences between two groups were
significant (P = .003).
Disease control rate (Complete response (CR) + Partial
response (PR) + Stable disease (SD) was significant higher
in patients with normal coagulation: 1 (3.6%) CR + 5
(17.9%) PR + 14 (50%) versus 0 CR + 1 (3.6%) PR + 11
(39.3%) SD (P = .003).
In Kaplan-Meier analysis, patients with hypercoagulabil-
ity had a significantly shorter overall survival than
patients with normal coagulation. Median survival was
8.2 (95%CI 7.2–9.2) and 14.6 (95%CI 12.4–16.8)
months, respectively (HR = .54, P = .0011). Survival
curves are given in Figure 1.
Multivariate analysis
In univariate analysis, patients (N = 289) with hypercoag-
ulability had significantly shorter survival than patients
with normal coagulation; median survivals of 8.9 and
16.3, respectively (P = .001).
Additional factors that were also associated with poor sur-
vival were MSKCC prognostic factors, increasing ECOG
performance status, shot time from diagnosis, non-clear
cell histology, and the presence of liver or bone metasta-
sis, more than 1 metastatic site.
Because of the large number of factors that were associ-
ated with hypercoagulability and/or survival in general
study population, multivariable analyses were conducted
to determine whether hypercoagulability was an inde-
Table 1: Extent of hypercoagulability
Extent of hypercoagulability Fibrinogen, mg/dl D-dimer, mg/ml Fibrin Monomer
Low 4.01–5 0.249–0.5 +
Intermediate 5,01–6 0.51–1 ++
High > 6.01 > 1.01 +++Journal of Experimental & Clinical Cancer Research 2009, 28:30 http://www.jeccr.com/content/28/1/30
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Table 2: Patient and disease characteristics
Factor No. (%) % with hypercoagulability P
Hypercoagulability
No 173 (60) - -
Yes 116 (40) - -
Extent of hypercoagulability
Low 13 (11) - -
Intermediate 24 (21) - -
High 79 (68) - -
Age
< 60 107 (37) 34
≥ 60 182 (63) 44 .004
Gender
Male 224 (78) 39
Female 65 (22) 45 .61
ECOG
0 110 (38) 38
1 170 (59) 41
29  ( 3 ) 4 4 . 0 7
Prior nephrectomy
No 25 (9) 48
Yes 264 (91) 40 .03
Time from diagnosis to on-study
≥ 1 y 165 (57) 30
< 1 y 124 (43) 53 < .001
Number of metastatic sites
0, 1 125 (43) 17
≥ 2 164 (57) 58 .001
Bone metastasis
No 199 (69) 38
Yes 90 (31) 44 .06
Liver metastasis
No 211 (73) 34
Yes 78 (27) 56 .02
MSKCC prognostic groups
Favorable 121 (42) 46
Intermediate 64 (22) 22
Poor 104 (36) 44 .84
Histology
Clear cell 231 (80) 42
Non-clear 58 (20) 33 .04
Venous thrombosis
No 275 37
Yes 14 100 -Journal of Experimental & Clinical Cancer Research 2009, 28:30 http://www.jeccr.com/content/28/1/30
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pendent predictor. The results of this analysis are summa-
rized in Table 4.
By using stepwise variable selection, hypercoagulability,
MSKCC risk group, non-clear RCC, number of metastatic
sites, and age were found to be independent predictors of
survival.
Discussion
Although advances in the treatment of metastatic RCC
have been made in recent years, the overall outcome of
this disease remains dismal. Despite encouraging results
with new treatment agents, their optimal incorporation
into clinical practice remains to be defined. Whether these
agents should be used as monotherapy or combined with
cytokines or other agents remains speculative. The role of
prognostic factors may help to define better these ques-
tions.
We sought to analyze metastatic RCC patients before can-
cer-specific treatment in N.N. Blokhin Russian Cancer
Research Center. The objective of this study was to deter-
mine whether an elevated coagulation level is a negative
predictor for survival and response to treatment in meta-
static RCC. Coagulation estimate is a simple, inexpensive
test that can be obtained before treatment and could help
to individualize therapy based on risk factor assessment.
Our results showed that 40% of patients had hypercoagu-
lability at treatment start. Hypercoagulability can be an
independent prognostic factor according to our data.
There were no studies which demonstrated prognostic
role of hypercoagulability and impact on response to
immunotherapy in metastatic RCC patients. However,
influence of disorders in the cellular hemostasis on sur-
vival of RCC patients was shown.
In the retrospective study by R. Suppiah et al. [9], 192 of
714 (25%) metastatic RCC patients had thrombocytosis.
In univariate analysis, patients with thrombocytosis had
significantly shorter survival than patients with normal
platelet count. Median survival was 8.4 months and 14.6
months, respectively (P < .001).
In another retrospective review by Symbas et al. [10], 147
of 259 (57%) metastatic RCC patients were found to have
at least once platelet count of > 400,000/μL before treat-
ment. Mean survival for these patients was 92 months,
compared with 151 months for those with normal plate-
let count (P = .005). Conclusions from this study were
that thrombocytosis could be manifestation of aggressive
tumors, with worse survival when compared with patients
with normal platelet count.
In a French study with more than 700 patients treated in
multicenter trials of cytokines, thrombocytosis was found
to be a significant predictor for survival on univariate
analysis [11].
The exact mechanism causing hypercoagulability as well
as thrombocytosis in association with RCC is unclear.
Possible mechanisms include overproduction of tumor
procoagulant and cytokines/growth factors stimulating
tissue factor pathway and megakaryocytes in case of
thrombocytosis.
Tissue factor is a glycoprotein responsible for initiating
extrinsic pathway of coagulation. Immunohistochemical
studies show that renal cancer cells express tissue factor on
their cell surfaces. Also, tissue factor antigen was detected
in the endothelium of vascular channels within the renal
tumors [12].
Table 3: Study and control groups.
Study group Control group Differences between groups, P value
hypercoagulability + - -
number of patients 28 28 -
male/female 20/8 21/7 0.33
median age 62 60.1 0.52
Prognostic factors
Good prognosis 15 pts (53.6%) 15 pts (53.6%) -
Poor prognosis 13 pts (46.4%) 13 pts (46.4%) -Journal of Experimental & Clinical Cancer Research 2009, 28:30 http://www.jeccr.com/content/28/1/30
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In vitro experimental studies demonstrate that inter-
leukins (IL), such as IL-6, IL-1 are able to cause hyperco-
agulability through stimulation of tissue factor activity
[13-15]. More than half of patients with metastatic RCC
have increased levels of circulating IL-6, which also corre-
lates with increased C-reactive protein levels. In a study by
Walther et al. [16], IL-6 was detected in 19 of 21 (90%)
renal cancer cell lines obtained from 20 patients wit met-
astatic RCC and also detected in the serum of 33 of 59
(56%) patients with metastatic RCC. Elevation of the
cytokines was associated with paraneoplastic manifesta-
tions including coagulation disorders.
Several theories have been proposed on how hypercoagu-
lability plays a significant role in tumor growth. One way
is an impact on proliferation and metastasis. The studies
of fibrinogen-deficient mice directly demonstrate that
fibrin(ogen) plays an important role in cancer pathophys-
iology and is a determinant of metastatic potential.
Fibrin(ogen) appears to facilitate metastasis by enhancing
the sustained adherence and survival of individual tumor
cell emboli in the vasculature of target organs. Fibrin deg-
radation products have been reported to have angiogenic,
chemoattractant, and anti-inflammatory activities and
these proteolytic derivatives of fibrin might also be of bio-
logic relevance to tumor progression. Thrombin induces
proliferation of metastatic cells [17,18]. Influence on ang-
iogenesis is the second important tumor growth mecha-
nism of hypercoagulability. Tissue factor and thrombin
are two substances which stimulate angiogenesis directly
[19-21]. Conversely, tissue factor and factor VIIa inhibi-
tors, as well as antithrombin block angiogenesis and
tumor growth [22,23].
Thrombi clots contain a variety of factors such as vascular
endothelial growth factor (VEGF), fibroblast growth fac-
tor (FGF), platelet-derived growth factor (PDGF), trans-
forming growth factor beta (TGF-β), IL-6, thrombin, and
fibrinogen, platelets. These modulators have been impli-
cated in various steps of tumor progression and in the
development of metastases [24]. A positive correlation
between serum VEGF levels and disease progression was
discovered in patients with different advanced cancers
[25]. Being one of the most significant proangiogenic
Overall survival (Kaplan-Meier analysis) Figure 1
Overall survival (Kaplan-Meier analysis). Median overall survival was 8.2 months for group with hypercoagulability, and 
14.6 months for group with normal coagulation. Differences were significant (HR = .54, P = .0011).Journal of Experimental & Clinical Cancer Research 2009, 28:30 http://www.jeccr.com/content/28/1/30
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cytokines, FGF contributes to migration, proliferation,
and differentiation of endothelium cells, and regulation
of the expression of proangiogenic molecules [26]. PDGF
induces angiogenesis by means of stimulation of VEGF
expression in tumor endothelial cells and by recruiting
pericytes to new blood vessels [27]. TGF-β plays an active
role in platelet aggregation and regulation of megakaryo-
cytes activity. This cytokine also regulates the activity of
the VEGF system and enhances endothelial cell survival
[28,29]. Stimulation of growth factors and expression of
their receptors by thrombin and tissue factors has been
detected in many trials [21,30,31].
Conclusion
Our study confirms the prevalence of hypercoagulability
associated with metastatic RCC. We have also demon-
strated that hypercoagulability determines worse survival
and response to treatment for metastatic RCC. With fur-
ther studies, this single independent prognostic factor
may provide a simple approach to improved risk stratifi-
cation of patients in future clinical trials protocols.
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